|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Tumor Biology |
Department of Neurosurgery, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, 683-8504 Japan (H.K., S.T., K.W., M.S., T.W.); Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 (S.T., T.E.)
1 Address correspondence and reprint requests to Hideki Kamitani, 36-1, Nishi-cho, Yonago, Tottori 683-8504 Japan.
Abstract
Histone deacetylase inhibitors that increase histone acetylation on transformed cells are being investigated as unique anticancer drugs. The aim of this investigation was to evaluate an antiproliferative activity of the histone deacetylase inhibitors sodium butyrate (NaBT) and trichostatin A on 5 glioma cell lines, T98G, A172, U-87 MG, U-118 MG, and U-373 MG, with the examination of the altered expressions in p21 and gelsolin genes. Treatment with 5-mM NaBT and 40 ng/ml trichostatin A for 48 h caused more than a 50% growth inhibition in 5 cell lines as measured by cell proliferation assays. An increase in histone acetylation was confirmed in each cell line. After treatment with 5 mM NaBT, T98G, A172, and U118 cells undergo apoptosis as indicated by DNA ladder formation. Treatment with NaBT and trichostatin A also decreased DNA synthesis as examined by the fluorescence-activated cell sorting analysis in T98G and U87 cells. In addition to the suppression of cell growth, the up regulation of p21 and gelsolin expression was observed after treatment with NaBT, especially in T98G cells. Maximum expression of p21 and gelsolin was observed within 24 h after treatment. Results from our in vitro studies indicate that the treatment of human glioma cells with one of the histone deacetylase inhibitors suppresses cell growth with decreasing DNA synthesis and stimulates apoptosis, and that associated molecular mechanisms responsible for these effects include increased histone acetylation as well as enhanced expression of p21 and gelsolin.
References
Archer, S.Y., Meng, S., Shei, A., and Hodin, R.A.
(1998) p21(WAF1) is required for butyrate-mediated growth
inhibition of human colon cancer cells. Proc. Natl. Acad. Sci.
U.S.A. 95,6791
-6796.
Asch, H.L., Winston, J.S., Edge, S.B., Stomper, P.C., and Asch, B.B. (1999) Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res. Treat. 55,179 -188.[Medline]
Ausio, J., and van Holde, K.E. (1986) Histone hyperacetylation: Its effects on nucleosome conformation and stability. Biochemistry 25,1421 -1428.[CrossRef][Medline]
Brandes, A.A., Pasetto, L.M., and Monfardini, S. (2000) New drugs in recurrent high grade gliomas. Anticancer Res. 20,1913 -1920.[Medline]
Butler, L.M., Agus, D.B., Scher, H.I., Higgins, B., Rose, A.,
Cordon-Cardo, C., Thaler, H.T., Rifkind, R.A., Marks, P.A., and Richon, V.M.,
(2000) Suberoylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of prostate cancer cells in vitro and in
vivo. Cancer Res. 60,5165
-5170.
Csordas, A. (1990) On the biological role of histone acetylation. Biochem. J. 265, 23-38.[Medline]
El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.M., and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75,817 -825.[CrossRef][Web of Science][Medline]
Engelhard, H.H., Homer, R.J., Duncan, H.A., and Rozental, J. (1998) Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J. Neurooncol. 37,97 -108.[CrossRef][Medline]
Frenay, M., Lebrun, C., Lonjon, M., Bondiau, P.Y., and Chatel, M. (2000) Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etopside (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur. J. Cancer 36,1026 -1031.
Gibson, P.R., Rosella, O., Wilson, A.J., Mariadason, J.M., Rickard,
K., and Barkla, D.H. (1999) Colonic epithelial cell activation
and the paradoxical effects of butyrate.
Carcinogenesis 20,539
-544.
Habeck, M. (1999) Gelsolin: A new marker for breast cancer? Mol. Med. Today 5, 503.[Medline]
Han, J.W., Ahn, S.H., Park, S.H., Wang, S.Y., Bae, G.-U., Seo,
D.-W., Kwon, H.-K., Hong, S., Lee, H.Y., Lee, Y.-W., and Lee, H.-W.
(2000) Apicidin, a histone deacetylase inhibitor, inhibits
proliferation of tumor cells via induction of p21(WAF1/Cip1) and gelsolin.
Cancer Res. 60,6068
-6074.
Hansen, L.A., Sigman, C.C., Andreola, F., Rossa, S.A., Kelloff,
G.J., and De Luca, L.M. (2000) Retinoids in chemoprevention and
differentiation therapy. Carcinogenesis
21,1271
-1279.
Harada, K., Kurisu, K., Sadatomo, T., Tahara, H., Tahara, E., and Ide, T. (2000) Growth inhibition of human glioma cells by transfection-induced p21 and its effects on telomerase activity. J. Neurooncol. 47,39 -46.[CrossRef][Medline]
Hargreaves, A.J., Yusta, B., Avila, J., Hesketh, J.E., Aranda, A., and Pascual, A. (1989) Sodium butyrate induces major morphological changes in C6 glioma cells that are correlated with increased synthesis of a spectrin-like protein. Brain. Res. Dev. Brain Res. 45,291 -295.[Medline]
Janne, P.A., and Mayer, R.J. (2000) Chemoprevention of
colorectal cancer. N. Engl. J. Med.
342,1960
-1968.
Kamitani, H., Geller, M., and Eling, T.E. (1998)
Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells
during apoptosis and cell differentiation. J. Biol.
Chem. 273,21569
-21577.
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., and Beppu, T.
(1993) Trapoxin, an antitumor cyclic tetrapeptide, is an
irreversible inhibitor of mammalian histone deacetylase. J. Biol.
Chem. 268,22429
-22435.
Kim, Y.B., Lee, K.H., Sugita, K., Yoshida, M., and Horinouchi, S. (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18,2461 -2470.[CrossRef][Web of Science][Medline]
Kwon, H.J., Owa, T., Hassig, C.A., Shimada, J., and Schreiber, S.L.
(1998) Depudecin induces morphological reversion of transformed
fibroblasts via the inhibition of histone deacetylase. Proc. Natl.
Acad. Sci. U.S.A. 95,3356
-3361.
McCaffrey, P.G., Newsome, D.A., Fibach, E., Yoshida, M., and Su,
M.S. (1997) Induction of gamma-globin by histone deacetylase
inhibitors. Blood 90,2075
-2083.
Marks, P.A., Richon, V.M., and Rifkind, R.A. (2000)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of
transformed cells. J. Natl. Cancer Inst.
92,1210
-1206.
Nakajima, H., Kim, Y.B., Terano, H., Yoshida, M., and Horinouchi, S. (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241,126 -133.[CrossRef][Web of Science][Medline]
Olivieri, N.F., Rees, D.C., Ginder, G.D., Thein, S.L., Brittenham, G.M., Waye, J.S., and Weatherall, D.J. (1997) Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 350,491 -492.[CrossRef][Medline]
Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H.,
Dahmoush, L., Kingma, D.M., Turner, M.L., Altemus, R., and Bates, S.E.
(2001) Inhibitor of histone deacetylation, depsipeptide
(FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A
case report. Blood 98,2865
-2868.
Rabizadeh, E., Shaklai, M., Nudelman, A., Eisenbach, L., and Rephaeli, A. (1993) Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 328,225 -229.[CrossRef][Medline]
Riggs, M.G., Whittaker, R.G., Neumann, J.R., and Ingram, V.M. (1977) n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268,462 -464.[CrossRef][Medline]
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K.,
Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. (1999) A
synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo
antitumor activity against human tumors. Proc. Natl. Acad. Sci.
U.S.A. 96,4592
-4597.
Sakai, N., Ohtsu, M., Fujita, H., Koike, T., and Kuzumaki, N. (1999) Enhancement of G2 checkpoint function by gelsolin transfection in human cancer cells. Exp. Cell. Res. 251,224 -233.[Medline]
Shapiro, W.R., Green, S.B., Burger, P.C., Mahaley, M.S., Jr., Selker, R.G., VanGilder, J.C., Robertson, J.T., Ransohff, J., Mealey, J.S., Jr., and Strike, T.A. (1989) Randomized trial of three chemotherapy and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J. Neurosurg. 71, 1-9.[Web of Science][Medline]
Stockhammer, G., Manley, G.T., Johnson, R., Rosenbulm, M.K., Samid, D., and Lieberman, F.S. (1995) Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J. Neurosurg. 83,672 -681.[Medline]
Takakura, K., Abe, H., Tanaka, R., Kitamura, K., Miwa, T., Takeuchi, K., Yamamoto, S., Kageyama, N., Handa, H., Mogami, H., Vishimoto, A., Uozumi, T., Matsutani, M., and Nomura, K. (1986) Effects of ACNU and radiotherapy on malignant glioma. J. Neurosurg. 64,53 -57.[Web of Science][Medline]
Thompson, M.A., Rosenthal, M.A., Ellis, S.L., Friend, A.J., Zorbas,
M.I., White-head, R.H., and Ramsay, R.G. (1998) c-Myb
down-regulation is associated with human colon cell differentiation, apoptosis
and decreased Bcl-2 expression. Cancer Res.
58,5168
-5175.
Van Lint, C., Emiliani, S., and Verdin, E. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245-253.[Web of Science][Medline]
Waldman, T., Kinzler, K.W., and Vogelstein, B. (1995)
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
Cancer Res. 55,5187
-5190.
Yoshida, M., Nomura, S., and Beppu, T. (1987) Effects
of trichostatins on differentiation of murine erythroleukemia cells.
Cancer Res. 47,3688
-3691.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Fu, C.-J. Shao, F.-R. Chen, H.-K. Ng, and Z.-P. Chen Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines Neuro Oncology, October 15, 2009; (2009) nop005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wakimoto, I. Wolf, D. Yin, J. O'Kelly, T. Akagi, L. Abramovitz, K. L. Black, H.-H. Tai, and H. P. Koeffler Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase Cancer Res., September 1, 2008; 68(17): 6978 - 6986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-N. Li, Q. Shu, J. M.-F. Su, L. Perlaky, S. M. Blaney, and C. C. Lau Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC Mol. Cancer Ther., December 1, 2005; 4(12): 1912 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Entin-Meer, A. Rephaeli, X. Yang, A. Nudelman, S. R. VandenBerg, and D. A. Haas-Kogan Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas Mol. Cancer Ther., December 1, 2005; 4(12): 1952 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Burzynski The Present State of Antineoplaston Research (1) Integr Cancer Ther, March 1, 2004; 3(1): 47 - 58. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
